Dr. Boritz pursued combined MD/PhD training at the University of Colorado Health Sciences Center in Denver, where he completed M.D. and Ph.D. in the Immunology Program studying HIV-specific CD4 T-cell responses with Dr. Cara Wilson. He completed his internship and residency in internal medicine in 2008 at the Johns Hopkins Hospital. Dr. Boritz joined the NIAID/NIH as a fellow in infectious diseases in 2008. Following the clinical portion of his fellowship, he joined Dr. Daniel Douek's laboratory at the Vaccine Research Center (VRC), where he worked to understand the cellular and molecular events that allow HIV reservoirs to persist in vivo. In 2017, Dr. Boritz was appointed as a tenure-track Investigator and Chief of the Virus Persistence and Dynamics Section (VPDS), VRC. Dr. Boritz is a recognized leader in the field of viral immunology and HIV persistence within infected CD4 T cell reservoirs, which represent a central barrier to HIV cure. His research seeks to elucidate immunologic and virologic mechanisms that allow viruses to persist in vivo by using diverse technologies, including a novel microfluidic sorting method termed FIND-seq, single-cell analysis, and high-throughput virus genome sequence analysis. He aims to exploit this knowledge for the development of therapeutic strategies antagonizing persistence and thereby curing viral infections. In addition, Dr. Boritz is conducting research on SARS-CoV-2 and other emerging viruses. The goal of these studies is to establish the mutational properties and patterns of in vivo genetic variation that may help in comprehending the potential of emerging viruses to acquire resistance against immune responses and medical countermeasures.